鞘内注射甲基强的松龙治疗多发性硬化研究

Study on Multiple Sclerosis Treatment by Intrathecal Injection of Methylprednisolone

目的:探讨鞘内注射甲基强的松龙治疗急性期多发性硬化(MS)的疗效。方法:将70例MS按主要治疗方法分为鞘内注射甲基强的松龙(MPS)组32例和MPS冲击组38例,比较治疗后2组不同时间的Kurtzke神经功能障碍量表(EDSS)评分减少数、住院总费用、日均住院费用、药品比例及平均住院天数。结果:鞘内注射MPS组5d时的EDSS评分减少数较MPS冲击组多,差异有统计学意义(P<0.05);15d时评分差异无统计学意义(P>0.05);鞘内注射MPS组的平均住院总费用、日均住院费用、平均住院天数、药品比例少于MPS冲击组,差异均有统计学意义(P<0.05)。结论:鞘内注射甲基强的松龙治疗MS,神经功能改善较快,住院天数及费用也较少。

Objective：To evaluate the effect of intrathecal injection of methylprednisolone in patients of acute multiple sclerosis（MS）.Methods：Seventy cases were divided into intrathecal methylprednisolone group（n=32） and methylprednisolone impact group（n=38）.The reduction of Kurtzke expanded disability status scale（EDSS） and the rate of side effects after treatment were evaluated.The average total cost of hospitalization,the average cost per hospital day and the proportional contribution of medications were analysed with the software of SPSS13.0.Results：The average improvement of EDSS after 5 days treatment was significantly obvious in intrathecal methylprednisolone group compared with that of methylprednisolone impact group（P 0.05）,but no difference after 15 days treatment（P 0.05）.There were significantly lower values in the average total cost of hospitalization,the average cost per hospital day,average hospitalization day and the proportional contribution of medications in intrathecal methylprednisolone group than those of methylprednisolone impact group（P 0.05）.Conclusion：The intrathecal methylprednisolone therapy showed a fast improvement of EDSS scale,reduced average hospitalization day and lower average total cost of hospitalization in patients with multiple sclerosis.